BR112023014247A2 - PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USE THEREOF - Google Patents
PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USE THEREOFInfo
- Publication number
- BR112023014247A2 BR112023014247A2 BR112023014247A BR112023014247A BR112023014247A2 BR 112023014247 A2 BR112023014247 A2 BR 112023014247A2 BR 112023014247 A BR112023014247 A BR 112023014247A BR 112023014247 A BR112023014247 A BR 112023014247A BR 112023014247 A2 BR112023014247 A2 BR 112023014247A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pharmaceutical compositions
- breast cancer
- treating breast
- breast cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000481 breast Anatomy 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract 3
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 abstract 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 abstract 1
- 101100420683 Drosophila melanogaster Sarm gene Proteins 0.000 abstract 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
composições farmacêuticas para tratar cânceres de mama e métodos de usos destas. esta invenção se refere ao tratamento de câncer de mama em um indivíduo. incluindo métodos para: tratar determinando-se, primeiro, a absorção de tumor de 18f-16beta-fluoro-5alfa-di-hidrotestosterona (18f-dht) e identificando-se o dito indivíduo como tendo um câncer de mama positivo para ar com base na absorção de tumor de f-dht, o que compreende administrar ao indivíduo uma quantidade terapeuticamente eficaz de um composto de modulador de receptor de androgênio seletivo (sarm) e um inibidor de quinase dependente de ciclina 4/6 (cdk 4/6).pharmaceutical compositions for treating breast cancer and methods of using them. This invention relates to the treatment of breast cancer in an individual. including methods for: treating by first determining tumor uptake of 18f-16beta-fluoro-5alpha-dihydrotestosterone (18f-dht) and identifying said individual as having an air-positive breast cancer based in tumor absorption of f-dht, which comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (sarm) compound and a cyclin-dependent kinase 4/6 (cdk 4/6) inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/151,108 US20210228529A1 (en) | 2012-07-13 | 2021-01-15 | Pharmaceutical compositions for treating breast cancers and methods of uses thereof |
| PCT/US2022/012631 WO2022155543A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical compositions for treating breast cancers and methods of uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014247A2 true BR112023014247A2 (en) | 2023-10-03 |
Family
ID=82448697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014247A BR112023014247A2 (en) | 2021-01-15 | 2022-01-14 | PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USE THEREOF |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4277613A1 (en) |
| JP (1) | JP2024503718A (en) |
| KR (1) | KR20230163362A (en) |
| CN (1) | CN116981451A (en) |
| AU (1) | AU2022208712A1 (en) |
| BR (1) | BR112023014247A2 (en) |
| CA (1) | CA3205212A1 (en) |
| IL (1) | IL304467A (en) |
| MX (1) | MX2023008375A (en) |
| WO (1) | WO2022155543A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115369089A (en) * | 2022-08-11 | 2022-11-22 | 中山大学孙逸仙纪念医院 | Two ER positive HER-2 negative breast cancer CDK4/6 inhibitor drug-resistant strains and construction method and application thereof |
| CN117257994B (en) * | 2023-11-21 | 2024-03-01 | 北京大学人民医院 | Construction method and application of animal model |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2425715B1 (en) * | 2005-08-31 | 2014-03-05 | University of Tennessee Research Foundation | Treating symptoms of renal disease with selective androgen receptor modulators (SARM) |
| US10987334B2 (en) * | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| JP7221699B2 (en) * | 2016-06-22 | 2023-02-14 | エリプセス ファーマ エルティーディー | AR+ methods of treating breast cancer |
-
2022
- 2022-01-14 BR BR112023014247A patent/BR112023014247A2/en unknown
- 2022-01-14 EP EP22740195.7A patent/EP4277613A1/en active Pending
- 2022-01-14 CA CA3205212A patent/CA3205212A1/en active Pending
- 2022-01-14 MX MX2023008375A patent/MX2023008375A/en unknown
- 2022-01-14 AU AU2022208712A patent/AU2022208712A1/en active Pending
- 2022-01-14 KR KR1020237027185A patent/KR20230163362A/en unknown
- 2022-01-14 WO PCT/US2022/012631 patent/WO2022155543A1/en active Application Filing
- 2022-01-14 CN CN202280021307.2A patent/CN116981451A/en active Pending
- 2022-01-14 JP JP2023543203A patent/JP2024503718A/en active Pending
-
2023
- 2023-07-13 IL IL304467A patent/IL304467A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304467A (en) | 2023-09-01 |
| EP4277613A1 (en) | 2023-11-22 |
| CA3205212A1 (en) | 2022-07-21 |
| MX2023008375A (en) | 2023-10-05 |
| KR20230163362A (en) | 2023-11-30 |
| WO2022155543A1 (en) | 2022-07-21 |
| AU2022208712A1 (en) | 2023-08-10 |
| CN116981451A (en) | 2023-10-31 |
| AU2022208712A9 (en) | 2024-09-19 |
| JP2024503718A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023014247A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USE THEREOF | |
| BR112021018295A2 (en) | Compositions and methods for treating cancer | |
| DOP2019000020A (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
| BRPI0517104A (en) | combination treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor | |
| AR109246A2 (en) | USE OF AN IMMUNOCATE PLAYING UNDERSTANDING AN ANTI-ErbB2 ANTIBODY FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| BR112018068512A2 (en) | methods for treating er +, her2-, hrg + breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| CO6290650A2 (en) | BREAST CANCER TREATMENT WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS | |
| BRPI0511760A (en) | gemcitabine treatment and an egfr inhibitor | |
| BRPI0517075A (en) | use of an epidermal growth factor receptor kinase inhibitor and ionization radiation for cancer treatment | |
| BRPI0622054B8 (en) | compound and pharmaceutical composition | |
| UY27943A1 (en) | COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS | |
| AR101504A1 (en) | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND / OR A CDK4 / 6 INHIBITOR | |
| PA8807801A1 (en) | CINESINE INHIBITORS AS THERAPEUTIC PRODUCTS FOR CANCER | |
| BRPI0510657A (en) | treatment with cisplatin and an egfr inhibitor | |
| ECSP077324A (en) | BICYCLIC AMIDAS AS INHIBITORS OF CINASA | |
| BR112021017350A2 (en) | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor | |
| UY33221A (en) | METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS | |
| BRPI0511800A (en) | irinotecan treatment (cpt-11) and an egfr inhibitor | |
| BR112023001792A2 (en) | COMBINATIONS FOR THE TREATMENT OF CANCER | |
| CO2022006466A2 (en) | Allosteric egfr inhibitors and methods of use thereof | |
| ECSP22098041A (en) | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE OF THESE | |
| BR112018076821A2 (en) | phthalazine derivatives as parp1, parp2 and / or tubulin inhibitors useful for cancer treatment | |
| CL2020002637A1 (en) | Cancer treatment methods. | |
| UY39061A (en) | RIP2-KINASE MACROCYCLIC INHIBITORS | |
| CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. |